The NextGen Oncotype DX test at Metropolis Healthcare is a specialized genomic assay designed to evaluate the recurrence risk of early-stage hormone receptor–positive breast cancer. This test analyzes multiple gene expressions to help determine the potential benefit of chemotherapy in addition to hormonal therapy. Metropolis Healthcare ensures accurate and reliable reporting through advanced molecular platforms. It supports clinicians in making personalized, evidence-based treatment decisions for breast cancer patients.
Price:
Rs. 340,000.00
Sample Type: Tissue
Fasting Not Required
Notes:N8197
Frequently Asked Questions (FAQ's):
What does the NextGen Oncotype DX test at Metropolis Healthcare include?
It measures the expression of multiple cancer-related genes to generate a recurrence score for breast cancer management.
How does Metropolis Healthcare perform the Oncotype DX test?
Metropolis Healthcare uses validated molecular methods to analyze gene expression from tumor tissue samples.
Who should consider taking the Oncotype DX test at Metropolis Healthcare?
Patients with early-stage, hormone receptor–positive breast cancer being evaluated for chemotherapy suitability should consider this test.
Is fasting required for the Oncotype DX test at Metropolis Healthcare?
No fasting is required; the test uses preserved tumor tissue provided by the treating clinician.
How long do results take at Metropolis Healthcare?
Results usually take 2–3 weeks due to detailed gene expression analysis.
Can this test at Metropolis Healthcare help guide chemotherapy decisions?
Yes, the recurrence score helps determine whether adding chemotherapy to hormonal therapy may be beneficial.
How reliable is the gene expression analysis at Metropolis Healthcare?
Metropolis Healthcare follows strict quality protocols to ensure high-accuracy and clinically relevant results.
Does this test support long-term planning at Metropolis Healthcare?
Yes, the recurrence score helps clinicians design personalized treatment and follow-up strategies.